Advertisement

Reactions Weekly

, Volume 1404, Issue 1, pp 5–5 | Cite as

Bevacizumab: as effective as ranibizumab for AMD, but safe?

Clinical study
  • 14 Downloads

Keywords

Vascular Endothelial Growth Factor Bevacizumab Ranibizumab Choroidal Neovascularisation Avastin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

REFERENCE

  1. 1.
    Martin DF, Maguire MG, Fine SL, Ying G-S, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd.Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmology: [11 pages], 2 May 2012. Available from: URL: http://dx.doi.org/10.1016/j.ophtha.2012.03.053
  2. 2.
    Chakravarty U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC.Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration: One-Year Findings from the IVAN Randomized Trial. Ophthalmology: 11 May 2012. Available from: URL: http://dx.doi.org/10.1016/j.ophtha.2012.04.015
  3. 3.
    Novartis.Recent publicly-funded CATT trial highlights serious safety concerns around unlicensed ocular bevacizumab use versus Lucentis. Media Release: 01 May 2012. Available from: URL: http://www.novartis.com
  4. 4.
    European Alliance for Access to Safe Medicines.Patient Safety Group Renews Call for Urgent Action to Protect Patients From Harm. Media Release: 17 May 2012. Available from: URL: http://www.eaasm.eu

Copyright information

© Adis International limited or Adis Data Information BV 2012

Personalised recommendations